Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Aditya Sarawgi

RARE PHOTOS: Vertex pharmaceuticals q1 2025 earnings what to expect - The Real Truth

With a market cap of $122.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) operates as a global biotechnology company that develops and commercializes therapies for treating cystic fibrosis (CF). The Boston, Massachusetts-based company is expected to release its Q1 2025 earnings after the market closes on Monday, May 5.

Ahead of this event, analysts expect VRTX to post adjusted earnings of $3.69 per share, down a staggering 14% from $4.29 per share reported in the same quarter last year. On a positive note, the company has surpassed Wall Street's bottom-line estimates in three of the past four quarters, but has missed the projections on one other occasion. In the previous quarter, its adjusted EPS of $3.54 surpassed the consensus estimates by 4.7%.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.